NASDAQ:AKBAAkebia Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akebia Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.88 +0.57 (+5.04 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$11.25Now: $11.88▼$11.9750-Day Range$6.90MA: $10.07▼$12.8552-Week Range$2.99Now: $11.88▼$13.17Volume1.86 million shsAverage Volume1.63 million shsMarket Capitalization$1.55 billionP/E RatioN/ADividend YieldN/ABeta1.42 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Akebia Therapeutics has a potential upside of 30.5% from its current price of $11.88.Amount of Analyst CoverageAkebia Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesAkebia Therapeutics has received 374 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAkebia Therapeutics has received 310 “underperform” votes. (Add your “underperform” vote.)Community SentimentAkebia Therapeutics has received 54.68% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote “Outperform” if you believe AKBA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,413.00 in company stock.Percentage Held by InsidersOnly 2.66% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions70.10% of the stock of Akebia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.59) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA Previous Symbol CUSIPN/A CIK1517022 Webwww.akebia.com Phone617-871-2098Debt Debt-to-Equity Ratio0.26 Current Ratio1.59 Quick Ratio1.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$335 million Price / Sales4.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book3.58Profitability EPS (Most Recent Fiscal Year)($1.63) Net Income$-279,660,000.00 Net Margins-76.39% Return on Equity-45.52% Return on Assets-25.47%Miscellaneous Employees324 Outstanding Shares130,266,000Market Cap$1.55 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:AKBA Rates by TradingView Receive AKBA News and Ratings via Email Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions How has Akebia Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AKBA shares have increased by 71.2% and is now trading at $11.88. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Akebia Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akebia Therapeutics. When is Akebia Therapeutics' next earnings date? Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Akebia Therapeutics. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.62) by $0.15. The biopharmaceutical company earned $88.48 million during the quarter, compared to the consensus estimate of $77.54 million. Akebia Therapeutics had a negative net margin of 76.39% and a negative return on equity of 45.52%. View Akebia Therapeutics' earnings history. What price target have analysts set for AKBA? 6 equities research analysts have issued 12 month price targets for Akebia Therapeutics' shares. Their forecasts range from $11.00 to $18.00. On average, they anticipate Akebia Therapeutics' stock price to reach $15.50 in the next year. This suggests a possible upside of 30.5% from the stock's current price. View analysts' price targets for Akebia Therapeutics. What are Wall Street analysts saying about Akebia Therapeutics stock? Here are some recent quotes from research analysts about Akebia Therapeutics stock: 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/12/2020) 2. HC Wainwright analysts commented, "We continue to believe that positive outcomes, on both safety and efficacy, from all four studies is highly likely, and with data directly comparing its outcomes to the current standard of care in both DD and NDD patients, we continue to believe Akebia is well positioned for clinical, regulatory and commercial success. Affirm Buy. $17 PT. We employ a rNPV model, driven by U.S. sales of vadadustat (early 2022 launch, 75% POS, $2.5B peak U.S. sales) and Auryxia (peak sales of $409M in 2024) out to 2028 (zero terminal value) discounted at 12.5%. Risks to our investment thesis and target price include: (1) failure in pivotal Phase 3 vadadustat studies; (2) failure to secure regulatory approval of vadadustat; (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing; and (4) intellectual property opposition." (9/9/2019) Has Akebia Therapeutics been receiving favorable news coverage? News stories about AKBA stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAkebia Therapeutics. Who are some of Akebia Therapeutics' key competitors? Some companies that are related to Akebia Therapeutics include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Emergent Biosolutions (EBS), Zai Lab (ZLAB), PPD (SDGR), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Evotec (EVTCY), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN) and GW Pharmaceuticals PLC- (GWPH). View all competitors. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), Chesapeake Energy (CHK), Energy Transfer LP Unit (ET), AbbVie (ABBV), FireEye (FEYE), TherapeuticsMD (TXMD), Bank of America (BAC), Corbus Pharmaceuticals (CRBP) and NVIDIA (NVDA). Who are Akebia Therapeutics' key executives? Akebia Therapeutics' management team includes the following people: Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)Mr. Douglas Jermasek, VP of Marketing & Strategy What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baupost Group LLC MA (13.46%), BlackRock Inc. (7.78%), State Street Corp (2.62%), Geode Capital Management LLC (1.40%), Wellington Management Group LLP (1.32%) and Nuveen Asset Management LLC (1.14%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. View institutional ownership trends for Akebia Therapeutics. Which major investors are selling Akebia Therapeutics stock? AKBA stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, Morgan Stanley, Nuveen Asset Management LLC, Clearbridge Investments LLC, BlackRock Inc., Bank of New York Mellon Corp, AQR Capital Management LLC, and UBS Group AG. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, Jason Amello, Michel Dahan, and Nicole R Hadas. View insider buying and selling activity for Akebia Therapeutics. Which major investors are buying Akebia Therapeutics stock? AKBA stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Wellington Management Group LLP, Atom Investors LP, Geode Capital Management LLC, Deutsche Bank AG, Virginia Retirement Systems ET AL, Squarepoint Ops LLC, and Trexquant Investment LP. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke. View insider buying and selling activity for Akebia Therapeutics. How do I buy shares of Akebia Therapeutics? Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $11.88. How big of a company is Akebia Therapeutics? Akebia Therapeutics has a market capitalization of $1.55 billion and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe. What is Akebia Therapeutics' official website? The official website for Akebia Therapeutics is www.akebia.com. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
